Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarkers of Vancomycin Hypersensitivity Reactions
NCT07605806Phase 2Active, not recruiting
- Sponsor
- Johns Hopkins University
- Start
- May 2026
- Primary completion
- May 2027
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vancomycin in bacterial infection, sponsored by Johns Hopkins University. Primary endpoint: Serum vancomycin concentration at 30 minutes. Started May 2026; status: active, not recruiting.
02
Drugs
vancomycin
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT07605806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07605806.